This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Alberta directory, so their publications, courses and email address may be missing. Find their university profile.
Latest funding
- $998,325
Proteinase-Activated Receptor-2 Agonists as Adjuvants for Mucosal Vaccination
CIHR · 2020 · Principal investigator
- $186,000
Determinants of Natural Killer Cell Ly49 Receptor Specificity
NSERC · 2016 · Principal investigator
- $668,730
Specificity and Function of Ly49 Natural Killer Cell Receptors
CIHR · 2008 · Nominated PI
Proteinase-Activated Receptor-2 Agonists as Adjuvants for Mucosal Vaccination
Principal investigators: Vliagoftis, Harissios; Kane, Kevin P
Keywords: Adjuvant; Aging; Cd8 Lymphocytes; Ferret; Immune System; Influenza; Mouse; Protease-Activated Receptors; Resident Memory Cells; Vaccination
Determinants of Natural Killer Cell Ly49 Receptor Specificity
Principal investigators: Kane, Kevin
Specificity and Function of Ly49 Natural Killer Cell Receptors
Principal investigators: Kane, Kevin P
Keywords: Molecular Modeling; Mutagenesis; Natural Killer Cells; Protein Structure; Receptors; Transfection
Canadian Network for Vaccines and Immunotherapeutics of Cancer and Chronic Viral Diseases (CANVAC) (2006 Renewal Competition)
Principal investigators: Sekaly, RafickPierre
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.